Spis treści:
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY
| POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
| UNI - EN REPORT No | 6 | / | 2025 | ||||||||
| Date of issue: | 2025-02-03 | ||||||||||
| Short name of the issuer | |||||||||||
| KRKA | |||||||||||
| Subject | |||||||||||
| Krka receives new S&P Global CSA Score | |||||||||||
| Official market - legal basis | |||||||||||
| art. 17. 1 MAR. | |||||||||||
| Unofficial market - legal basis | |||||||||||
| Contents of the report: | |||||||||||
| Based on the provisions of Article 26 of the Ljubljana Stock Exchange Rules, Article 158 of the Market in Financial Instruments Act, and Article 17 of Regulation (EU) No 596/2014, Krka, d. d., Novo mesto (hereinafter: Krka) discloses information regarding the acquisition of the S&P Global CSA Score. On 31 January 2025, Krka scored 56 (out of 100) in the 2024 S&P Global Corporate Sustainability Assessment. As of this date, Krka’s S&P Global CSA Score ranked among top 10% companies in the pharmaceutical industry in the S&P Global Corporate Sustainability Assessment and further improved the score compared to 2023. The received independent score reaffirms the outlined direction of the Krka Group’s sustainable management practices and ESG governance, where we prioritize our social responsibility and care for the health and well-being of patients. We provide them with access to high-quality, safe, and effective medicines produced in accordance with the highest standards of good manufacturing practice. In this process, we place significant emphasis on environmental protection and reducing our environmental impact. In the governance of the Krka Group, we adhere to the highest standards of business ethics, integrity, and transparent operations. The received score serves as both an encouragement and a commitment to further improve the sustainability practices in the Krka Group. This announcement will be published on the company’s website (www.krka.biz) starting from 3 February 2025, for a minimum period of 5 years. |
|||||||||||
| Annexes | |||||||||||
| File | Description | ||||||||||
| KRKA, TOVARNA ZDRAVIL D.D. | |||||||||||||
| (fullname of the issuer) | |||||||||||||
| KRKA | Farmaceutyczny (far) | ||||||||||||
| (short name of the issuer) | (sector according to clasification of the WSE in Warsow) |
||||||||||||
| 8501 | Nove Mesto | ||||||||||||
| (post code) | (city) | ||||||||||||
| Smarjeska | 6 | ||||||||||||
| (street) | (number) | ||||||||||||
| +386 7 331 21 11 | +386 7 332 15 37 | ||||||||||||
| (phone number) | (fax) | ||||||||||||
| (e-mail) | (web site) | ||||||||||||
| nie dotyczy | |||||||||||||
| (NIP) | (REGON) | ||||||||||||
| SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
| Date | Name | Position / Function | Signature | ||
| 2025-02-03 | Jože Colarič | President of the Management Board and CEO | |||
